马洛替酯对肝纤维化大鼠肝组织Smads蛋白表达的影响*

doi:10.3969/j.issn.1672-5069.2015.05.019

Abstract

Abstract: Objective To observe the effect of malotilate on the expression of the key signal conducting molecule smad3，smad4 and smad7 in rats with dimenthylnitrosamine（DMN）-induced hepatic fibrosis. Methods Sixty SD male rats were randomly divided into four groups，e.g. control，model，malotilate-and colchicine-treated group，with 15 in each. The hepatic fibrosis model was made by intraperitoneal injection of DMN，and rats were administered by gavage for 6 weeks. The Smad3，Smad4，Smad7 mRNA and their proteins were measured by real time PCR and Western blot，respectively. Results The Smad3 and smad4 mRNA and Smad3 and smad4 protein were（0.38±0.09），（0.29±0.08） and （0.16±0.05），（0.16±0.07）in the control，obviously decreased than in model group [0.84±0.08），（0.76±0.11） and （1.01±0.12），（0.94±0.11），P＜0.05]；the Smad7 mRNA and its protein in control group were（0.73±0.14）and （0.44±0.15），much higher than in the model group [（0.22±0.08）and （0.17±0.08），P＜0.05]；the Smad3 and smad4 mRNA and their proteins in malotilate group were [（0.52±0.10），（0.40±0.10） and （0.51±0.08），（0.41±0.09），significantly lower than in model P＜0.05] and the Smad7 mRNA and its protein in malotilate group were （0.48±0.09） and （0.39±0.10），significantly increased than in the model （P<0.05）. Conclusions Malotilate can inhibite hepatic fibrosis induced by DMN in rats，and the mechanism may be related to the down-regulation of Smad3 and smad4 and up-regulation of Smad7 expression.

Key words: Hepatic fibrosis, Malotilate, Smad3, smad4, Smad7, Rats

Huang Hong，Kang Yi，Huang Xuping，et al.. Effect of malotilate on expression of Smads protein in rats with dimenthylnitrosamine-induced hepatic fibrosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 525-529.

References

[1] Ismail MH，Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol，2009，15（1）:72-79.
[2] Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology，2008，134（6）:1655-1669.
[3] Farazi PA，DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer，2006，6（9）:674-687.
[4] Cohen MM Jr. TGF beta/Smad signaling system and its pathologic correlates. Am J Med Genet A，2003，116A（1）:1-10.
[5] Dooley S，Ten DP. TGF-beta in progression of liver disease. Cell Tissue Res，2012，347（1）: 245-256.
[6] Shi Y，Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell，2003，113（6）:685-700.
[7] Prosser CC，Yen RD，Wu J. Molecular therapy for hepatic injury and fibrosis:where are we. World J Gastroenterol，2006，12（4）:509-515.
[8] Friedman SL，Sheppard D，Duffield JS，et al. Therapy for fibrotic diseases:nearing the starting line. Sci Transl Med，2013，5（167）:167sr1.
[9] Stenback F，Ala-Kokko L，Ryhanen L. Morphological， immunohistochemical and ultrastructural changes in dimethylnitrosamine [correction of dimenthylnitrosamine] induced liver injury. Effect of malotilate. Histol Histopathol，1989，4（1）:95-104.
[10] Paakko P，Sormunen R，Risteli L，et al. Malotilate prevents accumulation of type III pN-collagen，type IV collagen，and laminin in carbon tetrachloride-induced pulmonary fibrosis in rats. Am Rev Respir Dis，1989，139（5）:1105-1111.
[11] 李旭，杨希山，吴平生，等. 马洛替酯抗肝纤维化的组织学及超微结构研究. 现代消化及介入诊疗杂志，2000，15 （1）:10-11.
[12] Ala-Kokko L，Pihlajaniemi T，Myers JC，et al. Gene expression of type I，III and IV collagens in hepatic fibrosis induced by dimethylnitrosamine in the rat. Biochem J，1987，244（1）:75-79.
[13] 阳学风，曾明新，张明亮，等. 马洛替酯抑制肝纤维化的实验与临床研究.世界华人消化杂志，1999，12（3）:43-45.
[14] 罗伟生，欧士钰，靳雅玲，等. 荔枝核总黄酮抗肝纤维化作用的实验研究. 重庆医学，2013，21（4）:373-375，378.
[15] 肝纤维化诊断及疗效评估共识. 药品评价，2007，8（4）:265-266.
[16] Lan HY，Chung AC. TGF-beta/Smad signaling in kidney disease. Semin Nephrol，2012，32（3）:236-243.
［17］陈峰，郑敏，陈智. Smad2 和 Smad3 在 TGF-β1信号转导中的作用. 国际流行病学传染病学杂志，2006，33（3）：187-189.
[18] Uemura M，Swenson ES，Gaca MD，et al. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell，2005，16（9）:4214-4224.
[19] Stroschein SL，Wang W，Luo K. Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor beta-induced smad-dependent transcriptional activation. J Biol Chem，1999，274（14）:9431-9441.
[20] Schnaper HW，Hayashida T，Poncelet AC. It's a Smad world: regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol，2002，13（4）:1126-1128.
[21] Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol，2004，85（2）:47-64.
[22] 王泽荣，王建浩，胡从莉,等. smad3基因小干扰RNA的序列设计及其表达载体的构建. 实用肝脏病杂志，2010，13（5）：328-330,368.
[23] 吴晓玲, 曾维政, 蒋明德,等. 肝纤维化大鼠肝组织Smads基因表达状况及意义. 世界华人消化杂志,2008,17（10）:1037-1041.

Effect of malotilate on expression of Smads protein in rats with dimenthylnitrosamine-induced hepatic fibrosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[2]	Xu Fei, Li Weirong.. Protective effects of astragaloside in rats with CCL₄-induced liver injuries [J]. Journal of Practical Hepatology, 2019, 22(6): 808-811.
[3]	Gao Lei, Cao Lei, Wang Ruifang, et al.. Protective effect of human umbilical cord mesenchymal stem cell transplantation on alcoholic liver injury in rats [J]. Journal of Practical Hepatology, 2019, 22(6): 812-815.
[4]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[5]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[6]	Lin Qiuxiang, Wang Xuewen, Huang Zuxiong, et al. Protective effects of breviscapine on liver and intestinal mucosal barrier functions in rats with hepatic ischemia-reperfusion injury [J]. Journal of Practical Hepatology, 2019, 22(5): 636-639.
[7]	Shi Xiaolong, Du Rui, Qin Geping, et al. Protective effect of sevoflurane on sepsis-induced liver injury in rats [J]. Journal of Practical Hepatology, 2019, 22(5): 640-643.
[8]	Wang Yan, Su Feng, Li Yuanyuan, et al. Protective effect of bee venom hemolysin on rats with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 474-477.
[9]	Zhou Liyun, Li Xiaotian, Li Li. 1,25（OH）₂D₃ inhibits hepatic fibrosis by regulating miR-146a levels in vitro and in vivo [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 333-336.
[10]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[11]	Guo Liping, Zhang Chenghong, Ning Baoshuo, et al.. An improved approach for seperating hepatocytes from neonatal rats in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 17-20.
[12]	Yusup Tursun, Zhao Yanxia.. Establishment of low-dose diethylnitrosamine-induced liver fibrosis model in rats [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 33-36.
[13]	Liu Enqiang, Chen Guo, Liao Xiuyong, et al.. Inhibition of TGF-β1/Smad/ERK passway by astaxanthin in rats with CCl₄-induced liver fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 842-846.
[14]	Pan Gaofeng, Fu Maoying, Gao Yufeng.. Endoplasmic reticulum stress in pathogenesis of hepatic fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 987-990.
[15]	Sui Ling, Du Jikun, Zheng Jingbin.. Protective effect of curcumin on CCl₄-induced acute liver injury in rats [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 709-712.